| | ||||
 |
|
|||
 >4x |
Module 85 |
| General Properties | |
|---|---|
| Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module. | |
| Num gene sets: | 2 |
| Num genes: | 51 (see 2632 additional genes for this module) |
| Num experiments: | 257 (86 induced, 171 repressed) |
| Parent module: | 199 |
| Children modules: | None |
| Gene sets | |
|---|---|
| Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates. | |
| transmembrane receptor protein tyrosine kinase activity | |
| transmembrane receptor protein kinase activity | |
| Enriched clinical annotations | |||||||
|---|---|---|---|---|---|---|---|
| For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched. | |||||||
| Clinical annotation | Category | P-value | Hits | Hits(%) | Module hits in category | Arrays in annotation | Arrays |
| Acute leukemia (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Cancer and cell line (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Cancer (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Hematologic cancer and cell line (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Hematologic cancer (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Hematologic samples and cell lines (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Leukemia (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Leukemia or leukemia cell line (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Monocytes (Leukemia*) | Leukemia* | 2.5e-29 | 59 | 34.5 | 171 | 141 | 1945 |
| Cell line (Breast cancer) | Breast cancer | 1.3e-12 | 16 | 94.1 | 17 | 30 | 152 |
| Liver tissue (Liver cancer*) | Liver cancer* | 1.2e-09 | 28 | 32.5 | 86 | 187 | 1945 |
| B cells (Leukemia) | Leukemia | 3.5e-09 | 43 | 72.8 | 59 | 62 | 141 |
| Liver tissue, cancer or cell line (Liver cancer*) | Liver cancer* | 4.2e-09 | 28 | 32.5 | 86 | 197 | 1945 |
| Breast cancer cell line (Breast cancer) | Breast cancer | 6.9e-09 | 11 | 64.7 | 17 | 17 | 152 |
| Hepatitis infected liver (Liver cancer*) | Liver cancer* | 1.5e-08 | 24 | 27.9 | 86 | 156 | 1945 |
| Primary blood mononuclear cells (Leukemia) | Leukemia | 8.7e-07 | 19 | 32.2 | 59 | 21 | 141 |
| Female hormonal cancer cell line (Breast cancer) | Breast cancer | 9.4e-07 | 9 | 52.9 | 17 | 15 | 152 |
| Bone marrow (Leukemia) | Leukemia | 1.6e-06 | 20 | 33.8 | 59 | 23 | 141 |
| Liver cancer cell line (Liver cancer) | Liver cancer | 1.5e-05 | 7 | 28 | 25 | 10 | 207 |
| Hematologic samples and cell lines (Various tumors) | Various tumors | 2.9e-05 | 7 | 100 | 7 | 37 | 154 |
| Hematologic samples (Various tumors) | Various tumors | 2.9e-05 | 7 | 100 | 7 | 37 | 154 |
| Cancer and cell line (Liver cancer) | Liver cancer | 2.9e-05 | 24 | 96 | 25 | 126 | 207 |
| Cell line (Liver cancer) | Liver cancer | 3.9e-05 | 7 | 28 | 25 | 11 | 207 |
| Non-tumor liver tissue (Liver cancer) | Liver cancer | 6.6e-05 | 20 | 71.4 | 28 | 76 | 207 |
| Activated B like DLBCL (B lymphoma) | B lymphoma | 0.0002 | 7 | 53.8 | 13 | 30 | 245 |
| Enriched GO annotations | ||||||
|---|---|---|---|---|---|---|
| For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column). | ||||||
| GO annotation | P-value | Hits | Hits(%) | Module genes | Genes in annotation | Genes |
| transmembrane receptor protein kinase activity | 2.1e-105 | 51 | 100 | 51 | 68 | 4566 |
| transmembrane receptor protein tyrosine kinase activity | 2.0e-97 | 48 | 94.1 | 51 | 62 | 4566 |
| protein kinase activity | 2.3e-81 | 48 | 94.1 | 51 | 102 | 4566 |
| porin activity | 3.6e-49 | 43 | 84.3 | 51 | 235 | 4566 |
| protein tyrosine kinase activity | 1.0e-47 | 36 | 70.5 | 51 | 120 | 4566 |
| receptor activity | 3.2e-47 | 51 | 100 | 51 | 582 | 4566 |
| transmembrane receptor activity | 5.9e-46 | 48 | 94.1 | 51 | 448 | 4566 |
| channel/pore class transporter activity | 3.7e-41 | 43 | 84.3 | 51 | 351 | 4566 |
| signal transducer activity | 3.1e-34 | 51 | 100 | 51 | 1026 | 4566 |
| protein amino acid phosphorylation | 1.9e-31 | 33 | 64.7 | 51 | 230 | 4566 |
| transmembrane receptor protein tyrosine kinase signaling pathway | 1.3e-29 | 21 | 41.1 | 51 | 52 | 4566 |
| response to DNA damage stimulus | 5.0e-27 | 33 | 64.7 | 51 | 310 | 4566 |
| eye photoreceptor cell fate commitment | 7.2e-27 | 18 | 35.2 | 51 | 38 | 4566 |
| compound eye morphogenesis (sensu Drosophila) | 4.2e-26 | 18 | 35.2 | 51 | 41 | 4566 |
| post-embryonic morphogenesis | 4.2e-26 | 18 | 35.2 | 51 | 41 | 4566 |
| post-embryonic development | 7.4e-26 | 18 | 35.2 | 51 | 42 | 4566 |
| response to stress | 1.1e-25 | 43 | 84.3 | 51 | 792 | 4566 |
| ATP binding | 4.2e-22 | 32 | 62.7 | 51 | 399 | 4566 |
| nucleotidyltransferase activity | 3.0e-21 | 32 | 62.7 | 51 | 425 | 4566 |
| integral to plasma membrane | 6.7e-21 | 36 | 70.5 | 51 | 612 | 4566 |
| hematopoietin/interferon-class (D200-domain) cytokine receptor activity | 4.4e-20 | 15 | 29.4 | 51 | 42 | 4566 |
| ephrin receptor activity | 6.9e-17 | 9 | 17.6 | 51 | 11 | 4566 |
| signal transduction | 2.4e-14 | 34 | 66.6 | 51 | 831 | 4566 |
| cell communication | 1.6e-11 | 34 | 66.6 | 51 | 1030 | 4566 |
| development | 8.7e-11 | 25 | 49.0 | 51 | 554 | 4566 |
| interleukin binding | 1.2e-10 | 8 | 15.6 | 51 | 25 | 4566 |
| interleukin receptor activity | 3.5e-10 | 8 | 15.6 | 51 | 28 | 4566 |
| morphogenesis | 5.5e-10 | 20 | 39.2 | 51 | 366 | 4566 |
| response to extracellular stimulus | 3.4e-09 | 22 | 43.1 | 51 | 500 | 4566 |
| enzyme linked receptor protein signaling pathway | 3.5e-07 | 6 | 11.7 | 51 | 27 | 4566 |
| cell surface receptor linked signal transduction | 3.1e-06 | 13 | 25.4 | 51 | 259 | 4566 |
| transmembrane receptor protein serine/threonine kinase activity | 2.5e-05 | 3 | 5.8 | 51 | 6 | 4566 |
| transmembrane receptor protein serine/threonine kinase signaling pathway | 2.5e-05 | 3 | 5.8 | 51 | 6 | 4566 |
| immune response | 2.8e-05 | 16 | 31.3 | 51 | 469 | 4566 |
| catalytic activity | 0.0001 | 32 | 62.7 | 51 | 1677 | 4566 |
| Visual display | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets. | |||||||||
| You can also view the images within GeneXPress by loading the module gxp file file. | |||||||||
|
|||||||||
